Sugi Predict

Sugi Predict / Targets / FRS2

FRS2

Fibroblast growth factor receptor substrate 2 · Q8WU20 · FRS2 on Sugi Atlas →

654 patent compounds predicted against FRS2, 552 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL16342978 SCHEMBL16342978 1.00 1/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL23928844) 0.98 1/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL30921860) 0.98 1/20
SCHEMBL16342952 SCHEMBL16342952 0.94 1/20
SCHEMBL16342739 SCHEMBL16342739 0.84 1/20
SCHEMBL16342562 SCHEMBL16342562 0.84 1/20
SCHEMBL17745066 SCHEMBL17745066 0.83 1/20
SCHEMBL14863028 SCHEMBL14863028 0.83 1/20
SCHEMBL16342594 SCHEMBL16342594 0.83 1/20
SCHEMBL14863974 SCHEMBL14863974 0.82 1/20
SCHEMBL16342888 SCHEMBL16342888 0.82 1/20
SCHEMBL14863295 SCHEMBL14863295 0.81 1/20
SCHEMBL16342642 SCHEMBL16342642 0.81 1/20
SCHEMBL14863279 SCHEMBL14863279 0.80 1/20
SCHEMBL16342458 SCHEMBL16342458 0.79 1/20
SCHEMBL16342572 SCHEMBL16342572 0.79 1/20
SCHEMBL16342623 SCHEMBL16342623 0.79 1/20
SCHEMBL18261760 SCHEMBL18261760 0.79 1/20
SCHEMBL16342717 SCHEMBL16342717 0.78 1/20
SCHEMBL23349648 SCHEMBL23349648 0.78 1/20

Clinical trials — most relevant to FRS2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients PHASE2ENROLLING_BY_INVITATION
Dovitinib(TKI258) in Patients With Castration-resistant Prostate Cancer PHASE2COMPLETED
Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer PHASE2WITHDRAWN
68 Gallium-Fibroblast Activating Protein Inhibitors-46 Positron Emission Tomography - Computerized Tomography for Molecular Assessment of Fibroblast Activation and Risk Assessment in Solid Tumors PHASE2UNKNOWN
Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer PHASE2COMPLETED
Investigator-initiated Clinical Trial of MIKE-1 PHASE1/PHASE2UNKNOWN
Iloprost in Preventing Lung Cancer in Patients at High Risk for This Disease PHASE2COMPLETED
Single Dose Investigator Initiated Pilot Study to Investigate CYTALUX (Pafolacianine) for Intraoperative Detection of Malignant Tissue in Subjects Undergoing Surgical Resection for Cancer. PHASE2RECRUITING
Study of Lenvatinib in Patients With Advanced Cancer and Aberrations in FGF/FGFR Signaling PHASE2WITHDRAWN
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer PHASE2RECRUITING
Study of Anlotinib Plus Chemoradiotherapy in Patients With Locally Advanced NSCLC PHASE1/PHASE2UNKNOWN
CAR-T Cell Therapy Targeting GPC3 in Patients with Advanced GPC3-Positive Hepatocellular Carcinoma PHASE1/PHASE2NOT_YET_RECRUITING
Postoperative EGFR-TKI Therapy forContralateral Pulmonary Nodules in Patients With EGFR-Mutant NSCLC（ARMOR2501） PHASE2RECRUITING
[18F]-AZAFOL AS POSITRON EMISSION TOMOGRAPHY (PET) TRACER in FR Positive Cancer Imaging PHASE1COMPLETED
Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2 PHASE1COMPLETED
Sorafenib, Epirubicin, Ifosfamide, and Radiation Therapy Followed By Surgery in Treating Patients With High-Risk Stage II or Stage III Soft Tissue Sarcoma PHASE1COMPLETED
Concentration and Activity of Lapatinib in Vestibular Schwannomas EARLY_PHASE1COMPLETED
The Development of Human Immunologic Assays Specific to Folate Receptor Antigen nanUNKNOWN
Pulsed Electro Magnetic Fields (PEMF) in Depression nanCOMPLETED
Cardiovascular Effects of Empagliflozine nanUNKNOWN
Role of FGF21 in Breast Cancer nanNOT_YET_RECRUITING
Clinical Research on 68Ga-FAPI PET/CMR in Cardiovascular Diseases nanRECRUITING
Evaluation of CEMIP in Pancreatic Cancer nanUNKNOWN
FGL2/Fibroleukin and Hepatitis C Virus Recurrence Post Liver Transplantation nanUNKNOWN
Understanding Evidence-Based Practice Patterns in Advanced NSCLC nanCOMPLETED
Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders nanRECRUITING
iCAGES-guided Precision Therapy for Cancers in Contrast to Standard Care or IHC-guided Theray nanRECRUITING
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
Genetic and Environmental Determinants of Triglycerides (GOLDN) nanCOMPLETED
Multiplex Mutation Detection Using Mass Spectrometry in Bladder Cancer nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a FRS2 binder may also engage these)

ProteinNameSimilarity
Q8C180 — 1.000 Q8C180 →
Q9Z1S8 — 0.988 Q9Z1S8 →
P84770 — 0.988 P84770 →
GAB1 GRB2-associated-binding protein 1 0.986 landscape →
Q9QYY0 — 0.986 Q9QYY0 →
A6QLU3 — 0.985 A6QLU3 →
Q99PF6 — 0.985 Q99PF6 →
P35569 — 0.984 P35569 →
Q5RJW5 — 0.984 Q5RJW5 →
Q9UQC2 — 0.984 Q9UQC2 →
Q9EQH1 — 0.982 Q9EQH1 →
Q91615 — 0.980 Q91615 →
Q9HAU0 — 0.980 Q9HAU0 →
Q8TEW8 — 0.980 Q8TEW8 →
Q8TEW0 — 0.980 Q8TEW0 →
PTPN14 Tyrosine-protein phosphatase non-receptor type 14 0.979 landscape →
P91621 — 0.979 P91621 →
Q5XJV7 — 0.979 Q5XJV7 →
Q28224 — 0.979 Q28224 →
Q62415 — 0.979 Q62415 →
Q498F0 — 0.978 Q498F0 →
Q62136 — 0.978 Q62136 →
A5D794 — 0.978 A5D794 →
Q9DF49 — 0.978 Q9DF49 →
P35570 — 0.978 P35570 →
Q96D71 — 0.978 Q96D71 →
IRS1 Insulin receptor substrate 1 0.978 landscape →
Q8K4S7 — 0.977 Q8K4S7 →
A3KMN5 — 0.977 A3KMN5 →
Q4V8Y7 — 0.977 Q4V8Y7 →